CHENGDU, China, Nov. 9 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ('TCM') based in Chengdu, China, today announced that management will hold a conference call to discuss its fiscal 2010 first quarter results at 10:30 a.m. ET on Friday, November 13, 2009. Financial results will be released prior to the market open on that day. A PowerPoint presentation which provides further details on the quarter and the recently announced Sichuan Jiangchuan Pharmaceutical Co. Ltd. joint venture will accompany management's discussion and can be accessed via the webcast link. Call Access Information: (877) 941-2321 from within the United States (480) 629-9714 if calling internationally Conference ID is 4182573 A replay will be available through November 21, 2009 and can be accessed by dialing (800) 406-7325 (U.S.), (303) 590-3030 (Int'l), Pin Code 4182573. Webcast Access Information Access Link: http://www.talkpoint.com/viewer/starthere.asp?pres=128645 You will need to have the Windows Media Player on your desktop. For a free download: http://www.microsoft.com/windows/windowsmedia/en/download/default.asp . About Tianyin Pharmaceuticals Tianyin is a manufacturer and supplier of modernized traditional Chinese medicine in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates three GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with three manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com/ . Safe Harbor Statement The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel: +86-158-2122-5642 Email: Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: Web: http://www.hcinternational.net/ DATASOURCE: Tianyin Pharmaceutical, Co., Inc. CONTACT: Allen Tang, Ph.D., MBA, Assistant to the CEO of TPI, +86-158- 2122-5642, or ; or Mr. Matthew Hayden of HC International, +1-561-245-5155, or , for TPI Web Site: Tianyin Pharmaceutical, Co., Inc.

Copyright